US Markets
Home›US Markets›M&A & Deals›Kimberly-Clark acquisition of Kenvue framed as margin…
Kimberly-Clark acquisition of Kenvue framed as margin boost
The deal would give Kimberly-Clark control of consumer staples tied to brands including Tylenol and Band-Aids, while the company’s dividend yield sits at 4.7% after a $1.28 quarterly payout.
Jim Cramer discussed Kimberly-Clark Corporation as a defensive holding and linked its outlook to its planned acquisition of Kenvue, the consumer health business previously spun off from Johnson & Johnson, according to a segment on CNBC's Mad Money.
Cramer said the combination would broaden Kimberly-Clark’s portfolio with essential health and wellness products such as Tylenol, Neutrogena, Listerine, and Band-Aids, which he characterized as steady demand generators that can support cash flow across economic cycles.
He also argued that the transaction offers a route to accelerated revenue growth and higher operating margins, alongside cost-reduction opportunities, while adding protection from foreign competition.
Cramer further pointed to valuation and shareholder returns, noting the stock trades at roughly 14 times this year’s earnings and that the company has raised its quarterly payout to $1.28 per share earlier this year, lifting the dividend yield to 4.7%, with 54 consecutive years of annual dividend increases.